BrainsWay

BrainsWay occupies a specialized position in medical devices and behavioral healthcare by combining a commercial neurostimulation platform with a growing clinical and reimbursement infrastructure. Its Deep TMS system uses patented H-Coils to stimulate deeper and broader brain regions than conventional TMS approaches, with applications in major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The FDA-cleared SWIFT protocol adds a shorter treatment pathway, reducing the acute course to six half-days, which directly addresses provider capacity and patient adherence. In the broader TMS market, NeuroStar and MagVenture are recognizable alternatives, while BrainsWay differentiates through its H-Coil portfolio, including the H1, H7, and H4 coils, and its focus on deeper stimulation. The company’s competitive position is supported by more than 60 clinical trials cited in its corporate materials, 32 granted patents, and expanding payer coverage, including more than 57 million covered lives reported for accelerated Deep TMS in June 2026. Its public-company status and $85.5 million in recorded funding provide greater capital-market visibility than many private behavioral-health technology providers, although adoption remains dependent on clinical economics, reimbursement, and provider implementation.

BrainsWay’s trajectory shows a shift from device development and regulatory validation toward protocol expansion, reimbursement coverage, and ecosystem investment. Founded in 2003 and public since 2007, the company recorded five post-IPO equity rounds totaling $85.5 million, including $45.2 million in 2021 and $20 million from Valor Equity Partners on Sep 30, 2024. Product development has recently focused on accelerating treatment delivery: FDA clearance on Sep 16, 2025 enabled commercial availability of an accelerated Deep TMS protocol, and the SWIFT program generated additional validation data on Mar 4, 2026 and 12-month durability data on Jun 9, 2026. Commercial momentum is also reflected in payer expansion, with favorable coverage for accelerated Deep TMS reaching more than 57 million covered lives by Jun 22, 2026. BrainsWay is extending beyond equipment sales through practice support, referrals, and strategic investments in care delivery. The May 19, 2026 Hopemark partnership and $1.5 million investment targeted North American access, while the company reported investments in several behavioral-health and neurostimulation businesses during 2025 and 2026. The main inflection point is the transition from a hardware-led model to a protocol-and-network model tied to reimbursement and clinical workflow.